End-of-day quote
Nasdaq
06:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
0.3689
USD
|
-0.30%
|
|
-0.30%
|
-44.11%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
290.5
|
61.84
|
29.4
|
Enterprise Value (EV)
1 |
256.1
|
-1.052
|
31.1
|
P/E ratio
|
-2.65
x
|
-0.63
x
|
-0.41
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
105
x
|
14.4
x
|
11.5
x
|
EV / Revenue
|
92.7
x
|
-0.25
x
|
12.1
x
|
EV / EBITDA
|
-6.45
x
|
0.02
x
|
-0.51
x
|
EV / FCF
|
-14,290,608
x
|
17,088
x
|
-413,869
x
|
FCF Yield
|
-0%
|
0.01%
|
-0%
|
Price to Book
|
-1.34
x
|
0.49
x
|
0.45
x
|
Nbr of stocks (in thousands)
|
29,466
|
43,857
|
44,545
|
Reference price
2 |
9.860
|
1.410
|
0.6600
|
Announcement Date
|
4/1/22
|
3/22/23
|
3/21/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.085
|
0.566
|
2.761
|
4.286
|
2.561
|
EBITDA
1 |
-21.36
|
-24.13
|
-39.68
|
-69.23
|
-60.88
|
EBIT
1 |
-21.78
|
-24.69
|
-40.45
|
-70.63
|
-64.44
|
Operating Margin
|
-25,625.88%
|
-4,362.9%
|
-1,464.9%
|
-1,647.9%
|
-2,516.28%
|
Earnings before Tax (EBT)
1 |
-21.16
|
-19.86
|
-55.32
|
-58.21
|
-83.41
|
Net income
1 |
-21.16
|
-19.86
|
-55.32
|
-58.21
|
-71.06
|
Net margin
|
-24,890.59%
|
-3,509.19%
|
-2,003.59%
|
-1,358.14%
|
-2,774.62%
|
EPS
2 |
-1.557
|
-1.433
|
-3.717
|
-2.229
|
-1.601
|
Free Cash Flow
|
-
|
-14.3
|
-17.92
|
-61.54
|
-75.14
|
FCF margin
|
-
|
-2,526.28%
|
-648.99%
|
-1,435.75%
|
-2,933.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/22
|
2/14/22
|
4/1/22
|
3/22/23
|
3/21/24
|
Fiscal Period: December |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
1.766
|
0.059
|
1.286
|
0.937
|
0.338
|
EBITDA
|
-
|
-19.57
|
-
|
-
|
-
|
EBIT
1 |
-17.08
|
-20.02
|
-19.83
|
-19.64
|
-18.18
|
Operating Margin
|
-967.44%
|
-33,925.42%
|
-1,542.3%
|
-2,095.52%
|
-5,380.18%
|
Earnings before Tax (EBT)
1 |
-
|
-18.21
|
-18.72
|
-18.7
|
-36.62
|
Net income
1 |
-16.64
|
-18.21
|
-18.72
|
-18.7
|
-36.62
|
Net margin
|
-942.24%
|
-30,864.41%
|
-1,455.83%
|
-1,995.41%
|
-10,832.84%
|
EPS
2 |
-0.3800
|
-0.4200
|
-0.4200
|
-0.4200
|
-0.3400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/22
|
3/22/23
|
5/9/23
|
8/11/23
|
11/14/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
1.7
|
Net Cash position
1 |
3.02
|
16.5
|
34.5
|
62.9
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.0279
x
|
Free Cash Flow
|
-
|
-14.3
|
-17.9
|
-61.5
|
-75.1
|
ROE (net income / shareholders' equity)
|
-
|
-81.2%
|
-121%
|
-62%
|
-85.9%
|
ROA (Net income/ Total Assets)
|
-
|
-36.7%
|
-34.9%
|
-31.8%
|
-26.8%
|
Assets
1 |
-
|
54.17
|
158.7
|
183
|
264.9
|
Book Value Per Share
2 |
-2.900
|
-4.050
|
-7.340
|
2.890
|
1.460
|
Cash Flow per Share
2 |
0.3900
|
2.110
|
3.690
|
1.310
|
0.7900
|
Capex
1 |
2
|
1.16
|
5.54
|
41.4
|
12
|
Capex / Sales
|
2,348.24%
|
205.12%
|
200.76%
|
965.33%
|
470.05%
|
Announcement Date
|
2/14/22
|
2/14/22
|
4/1/22
|
3/22/23
|
3/21/24
|
|
1st Jan change
|
Capi.
|
---|
| -44.11% | 16.88M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|